Strata Skin Sciences Faces Nasdaq Delisting

Strategic Insights -

Strata Skin Sciences, Inc., a publicly traded company, is at risk of delisting from the Nasdaq Stock Market after failing to meet the minimum stockholders' equity requirement. The company received a notice from Nasdaq on August 19, 2025, advising them that they do not meet the stockholders' equity requirement of at least $2,500,000. Despite this, the company's common stock continues to trade on the Nasdaq Capital Market, subject to compliance with other listing requirements. The company has 45 calendar days to submit a plan to regain compliance, with an additional 180 calendar days to implement the plan.

Key Takeaways:

  • Strata Skin Sciences, Inc. received a notice from Nasdaq on August 19, 2025, stating that they do not meet the minimum stockholders' equity requirement for continued listing.
  • The company's stockholders' equity is reported to be below the required $2,500,000, as stated in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
  • Nasdaq has given the company 45 calendar days, until October 3, 2025, to submit a plan to regain compliance.
  • The company is currently evaluating various courses of action to regain compliance with the stockholders' equity requirement.
  • If the company's plan to regain compliance is not accepted, or if they do not meet other Nasdaq requirements, their common stock may become subject to delisting.
  • The company may appeal any delist determination and request a hearing with the Nasdaq Panel.

Statistics:

  • The minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market is $2,500,000.
  • Strata Skin Sciences' stockholders' equity is reported to be below the required amount.
  • The company has 45 calendar days from August 19, 2025, to submit a plan to regain compliance.
  • The company has an additional 180 calendar days to implement their plan to regain compliance.

Sources:

  • Form 8-K (Current Report) filed with the U.S. Securities and Exchange Commission on August 22, 2025.
  • Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
  • Nasdaq Listing Rule 5550(b)(1).
  • Private Securities Litigation Reform Act of 1995, as amended.